- Home
- CNNE vs NBTX Comparison
CNNE vs NBTX Comparison
Compare CNNE & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- NBTX
- Stock Information
- Founded
- CNNE 2014
- NBTX 2003
- Country
- CNNE United States
- NBTX France
- Employees
- CNNE N/A
- NBTX N/A
- Industry
- CNNE Restaurants
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- CNNE Consumer Discretionary
- NBTX Health Care
- Exchange
- CNNE Nasdaq
- NBTX Nasdaq
- Market Cap
- CNNE 1.1B
- NBTX 1.3B
- IPO Year
- CNNE N/A
- NBTX 2020
- Fundamental
- Price
- CNNE $18.74
- NBTX $19.30
- Analyst Decision
- CNNE Buy
- NBTX Strong Buy
- Analyst Count
- CNNE 3
- NBTX 1
- Target Price
- CNNE $23.33
- NBTX $8.00
- AVG Volume (30 Days)
- CNNE 570.1K
- NBTX 142.7K
- Earning Date
- CNNE 11-11-2025
- NBTX 09-30-2025
- Dividend Yield
- CNNE 3.21%
- NBTX N/A
- EPS Growth
- CNNE N/A
- NBTX N/A
- EPS
- CNNE N/A
- NBTX N/A
- Revenue
- CNNE $437,200,000.00
- NBTX $11,930,711.00
- Revenue This Year
- CNNE N/A
- NBTX N/A
- Revenue Next Year
- CNNE N/A
- NBTX $114.97
- P/E Ratio
- CNNE N/A
- NBTX N/A
- Revenue Growth
- CNNE N/A
- NBTX N/A
- 52 Week Low
- CNNE $15.92
- NBTX $2.76
- 52 Week High
- CNNE $22.36
- NBTX $30.35
- Technical
- Relative Strength Index (RSI)
- CNNE 51.90
- NBTX 46.34
- Support Level
- CNNE $18.25
- NBTX $23.31
- Resistance Level
- CNNE $18.87
- NBTX $28.51
- Average True Range (ATR)
- CNNE 0.41
- NBTX 2.31
- MACD
- CNNE 0.04
- NBTX -1.27
- Stochastic Oscillator
- CNNE 69.68
- NBTX 8.55
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.